Urine Omics Predicting IO Therapy Responses in mRCC Patients

Overview

The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.

Full Title of Study: “Urine Metabolomics and Proteomics Profiling to Predict the Responses and Adverse Events of Immuno-Oncology-based Therapy in Patients With Advanced Renal Cell Carcinoma”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2025

Detailed Description

This is a multi-center single-arm translational study where patients with mRCC who are to receive pre-determined IO-based therapy will be invited to participate the study. After signing the approved informed consent, eligible and consenting subjects will donate their fresh urine samples for subsequent untargeted metabolomics and proteomics study via GS-MS/MS and/or LC-MS/MS to identify potential metabolite and protein markers that are able to predict efficacy and side effects of IO-based therapies. All subjects in the first-line, maintenance after 1st line, second-line, or subsequent lines of IO-based therapy will be invited and recruited, but those who have received any IO-based therapy before the study can NOT be recruited.

Interventions

  • Other: No intervention required
    • No intervention required

Arms, Groups and Cohorts

  • Cohort A
    • Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.
  • Cohort B
    • Validation cohort will be recruited in the next 36 months of the study period.

Clinical Trial Outcome Measures

Primary Measures

  • Objective Response Rate (ORR)
    • Time Frame: 7 years
  • Progression-free survival (PFS)
    • Time Frame: 7 years
  • Duration of response (DOR)
    • Time Frame: 7 years
  • Overall survival (OS)
    • Time Frame: 7 years
  • Adverse event of special interest (AESI)
    • Time Frame: 7 years

Participating in This Clinical Trial

Inclusion Criteria

1. Age > 20 years 2. Subjects diagnosed as advanced or metastatic renal cell carcinoma (a/mRCC) 3. Subjects who are about to receive IO-based therapy 4. ECOG performance 0, 1, 2, and 3 5. Life expectancy >3 months 6. eGFR > 15 ml/min/1.73 m2 (Stage IV Chronic Kidney Disease or better) 7. Willing to sign the informed consent form Exclusion Criteria:

1. Subjects NOT willing to sign the informed consent form 2. Subjects with active infection or active urinary tract infection, as shown by urinary WBC > 5/HPF 3. Subjects having co-existing other malignancies that need active treatment. Those subjects with other malignancies that do not need active treatment are allowed to join the study. 4. Subjects taking any immune-modulating agents, including but not limited to corticosteroid, immune-suppressants, etc. at the discretion of recruiting investigators 5. Subjects who have taken any IO-based therapy before. 6. Subjects who have received other systemic anti-cancer therapies within 4 weeks of screening are not allowed. However, subjects who had a washout period of the above agents for >4 weeks are allowed to enroll. Subjects who have received or are receiving targeted therapy are allowed to join the study.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National Taiwan University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Yeong Shiau Pu, MD PhD, 886-2-23123456, pu5249@ntuh.gov.tw

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.